Anthea Pharma's Bupivacaine Hydrochloride ANDA220493 Receives AP Status
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Bupivacaine Hydrochloride submitted by Anthea Pharma.
Company
Pharmaceutical intelligence for Anthea Pharma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.